产品信息
抗原名称
BTK
商品描述
FM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC??’s = 2.5 μM (recombinant BTK) and 17.2 μM (human BTK).
分子量
360
纯度
>98%
可溶性
DMSO 72 mg/mL warmed (200.0 mM)
外观
Powder
In vitro(体外研究)
In BTK+ B-lineage leukemic cells, LFM-A13 enhances their sensitivity to ceramide- or vincristine-induced apoptosis. In BCL-1 cells, NALM-6 cells, or normal BALB/c splenocytes, LFM-13 inhibits the enzymatic activity of BTK in BCL-1 cells without affecting the BTK protein expression levels In human neutrophils, LFM-A13 decreases the tyrosine phosphorylation induced by fMet-Leu-Phe and inhibits the production of superoxide anions and the stimulation of adhesion, chemotaxis, and phospholipase D activity.
In vivo(体内研究)
In BALB/c mice bearing BCL-1 leukemia, combination of LFM-A13 (50 mg/kg/day i.p.) and the standard triple-drug VPL prolongs the median survival time. In primary myeloma-bearing SCID-rab mice, LFM-A13 inhibits osteoclast activity, prevents myeloma-induced bone resorption and suppresss myeloma growth.
背景
别名
LFMA13
分子式
C11H8Br2N2O2
CAS号
244240-24-2
制备和贮存
保存方式
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
参考图片
本文来自投稿，不代表本人立场，如若转载，请注明出处：http://www.iamyjet.com/article/13870.html